Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Treasury Shares: 2016-2024

Historic Treasury Shares for Syndax Pharmaceuticals (SNDX) over the last 2 years, with Dec 2024 value amounting to $1.3 million.

  • Syndax Pharmaceuticals' Treasury Shares rose 151.06% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year increase of 151.06%. This contributed to the annual value of $1.3 million for FY2024, which is 151.06% up from last year.
  • As of Q4 2024, Syndax Pharmaceuticals' Treasury Shares stood at $1.3 million, which was up 151.06% from $519,436 recorded in Q4 2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Treasury Shares peaked at $1.3 million during Q4 2024, and registered a low of $18,500 during Q4 2020.
  • Over the past 3 years, Syndax Pharmaceuticals' median Treasury Shares value was $392,288 (recorded in 2023), while the average stood at $470,442.
  • Data for Syndax Pharmaceuticals' Treasury Shares shows a peak YoY surged of 615.31% (in 2021) over the last 5 years.
  • Syndax Pharmaceuticals' Treasury Shares (Quarterly) stood at $18,500 in 2020, then surged by 615.31% to $132,333 in 2021, then skyrocketed by 69.87% to $224,788 in 2022, then skyrocketed by 131.08% to $519,436 in 2023, then skyrocketed by 151.06% to $1.3 million in 2024.
  • Its last three reported values are $1.3 million in Q4 2024, $519,436 for Q4 2023, and $524,236 during Q3 2023.